{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T01:16:24Z","timestamp":1777511784667,"version":"3.51.4"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,5,10]],"date-time":"2023-05-10T00:00:00Z","timestamp":1683676800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,5,10]],"date-time":"2023-05-10T00:00:00Z","timestamp":1683676800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Gastroenterol"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Nonalcoholic fatty liver disease (NAFLD) is the most common cause of chronic liver disease. The serum level of soluble CD163 (sCD163), a macrophage activation marker, is associated with liver tissue changes; however, its prognostic value is unknown. Here, we determined the utility of sCD163 as a marker for hepatocellular carcinoma (HCC) and prognostic marker for NAFLD.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>This retrospective study obtained data regarding serum sCD163 levels, liver histology, and background factors associated with NAFLD in 287 patients (men\/women, 140\/147; average age, 53\u2009\u00b1\u200914 years) with NAFLD who underwent liver biopsy. Repeated liver biopsies of 287 patients with NAFLD (5.0\u2009\u00b1\u20092.7 years) were compared regarding serum sCD163 levels and liver tissue changes (stage, grade, steatosis, and NAFLD activity score).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Serum sCD163 levels increased with the progression of liver fibrosis and inflammation (both P\u2009&lt;\u20090.05) and were particularly helpful in distinguishing cases of Grade 4 fibrosis (P\u2009&lt;\u20090.001). Levels of sCD163 significantly decreased in patients with NAFLD exhibiting alleviated fibrosis and inflammation (P\u2009&lt;\u20090.05). We could also predict the development of HCC and associated mortality based on serum sCD163 levels at the time of NAFLD diagnosis. Serum sCD163 levels were higher in patients with HCC than in patients without HCC (1074\u2009\u00b1\u2009379 ng\/ml vs. 669\u2009\u00b1\u2009261 ng\/ml; P\u2009&lt;\u20090.0001), and the same trend was observed for mortality.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>The serum sCD163 level reflects the progression of fibrosis and inflammation in liver tissues, showing much promise as a noninvasive biomarker for nonalcoholic steatohepatitis and NAFLD as well as a possible predictor of HCC development and patient prognosis.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12876-023-02786-4","type":"journal-article","created":{"date-parts":[[2023,5,10]],"date-time":"2023-05-10T13:07:55Z","timestamp":1683724075000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Soluble CD163 is a predictor of fibrosis and hepatocellular carcinoma development in nonalcoholic steatohepatitis"],"prefix":"10.1186","volume":"23","author":[{"given":"Miwa","family":"Kawanaka","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ken","family":"Nishino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mayuko","family":"Kawada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katsunori","family":"Ishii","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomohiro","family":"Tanikawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryo","family":"Katsumata","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Noriyo","family":"Urata","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jun","family":"Nakamura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mitsuhiko","family":"Suehiro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ken","family":"Haruma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hirofumi","family":"Kawamoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,5,10]]},"reference":[{"key":"2786_CR1","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1002\/hep.28431","volume":"64","author":"ZM Younossi","year":"2016","unstructured":"Younossi ZM, Koenig AB, Abdelatif D, Fazel Y, Henry L, Wymer M. Global epidemiology of nonalcoholic fatty liver disease\u2014Meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology. 2016;64:73\u201384.","journal-title":"Hepatology"},{"key":"2786_CR2","doi-asserted-by":"publisher","first-page":"1388","DOI":"10.1016\/j.jhep.2015.11.004","volume":"64","author":"European Association for the Study of the Liver (EASL)","year":"2016","unstructured":"European Association for the Study of the Liver (EASL). European Association for the study of diabetes (EASD); European Association for the study of obesity (EASO). EASL-EASD-EASO clinical practice guidelines for the management of non-alcoholic fatty liver disease. J Hepatol. 2016;64:1388\u2013402.","journal-title":"J Hepatol"},{"key":"2786_CR3","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1002\/hep.29367","volume":"67","author":"N Chalasani","year":"2018","unstructured":"Chalasani N, Younossi Z, Lavine JE, Charlton M, Cusi K, Rinella M, et al. The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the study of Liver Diseases. Hepatology. 2018;67:328\u201357.","journal-title":"Hepatology"},{"key":"2786_CR4","unstructured":"Huang DQ, EI-Serag HB, Loomba R. Global epidemiology of NAFLD-related HCC: trends, predictions, risk factors and prevention. Nat Rev Gastroenterol Hepatol. 2021:18223\u201338."},{"key":"2786_CR5","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1002\/hep.31288","volume":"73","author":"KA McGlynn","year":"2021","unstructured":"McGlynn KA, Petrick JL, EI-Serag H. Epidemiology of hepatocellular carcinoma. Hepatology. 2021;73:4\u201313.","journal-title":"Hepatology"},{"key":"2786_CR6","doi-asserted-by":"publisher","first-page":"617","DOI":"10.3109\/07853890.2010.518623","volume":"43","author":"G Musso","year":"2011","unstructured":"Musso G, Gambino R, Cassader M, Pagano G. Meta-analysis: natural history of non-alcoholic fatty liver disease (NAFLD) and diagnostic accuracy of non-invasive tests for liver disease severity. Ann Med. 2011;43:617\u201349.","journal-title":"Ann Med"},{"key":"2786_CR7","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1016\/j.cgh.2014.04.014","volume":"13","author":"S Singh","year":"2015","unstructured":"Singh S, Allen AM, Wang Z, Prokop LJ, Murad MH, Loomba R. Fibrosis progression in nonalcoholic fatty liver vs nonalcoholic steatohepatitis: a systematic review and meta-analysis of paired-biopsy studies. Clin Gastroenterol Hepatol. 2015;13:643\u201354.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2786_CR8","doi-asserted-by":"crossref","unstructured":"Angulo P, Kleiner DE, Dam-Larsen S, Adams LA, Bjornsson ES, Charatcharoenwitthaya P et al. Liver fibrosis, but no other histologic features, is associated with long-term outcomes of patients with nonalcoholic fatty liver disease. Gastroenterology. 2015;149: 389 \u2013 97.e10.","DOI":"10.1053\/j.gastro.2015.04.043"},{"key":"2786_CR9","doi-asserted-by":"publisher","first-page":"1557","DOI":"10.1002\/hep.29085","volume":"65","author":"PS Dulai","year":"2017","unstructured":"Dulai PS, Singh S, Patel J, Soni M, Prokop LJ, Younossi Z, et al. Increased risk of mortality by fibrosis stage in nonalcoholic fatty liver disease: systematic review and meta-analysis. Hepatology. 2017;65:1557\u201365.","journal-title":"Hepatology"},{"key":"2786_CR10","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.1016\/j.jhep.2017.07.027","volume":"67","author":"H Hagstr\u00f6m","year":"2017","unstructured":"Hagstr\u00f6m H, Nasr P, Ekstedt M, Hammar U, St\u00e5l P, Hultcrantz R, et al. Fibrosis stage but not NASH predicts mortality and time to development of severe liver disease in biopsy-proven NAFLD. J Hepatol. 2017;67:1265\u201373.","journal-title":"J Hepatol"},{"key":"2786_CR11","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.cgh.2002.01.002","volume":"S1542\u20133565","author":"H Fujii","year":"2022","unstructured":"Fujii H, Iwaki M, Hyashi H, Toyoda H, Oeda S, Hyogo H, et al. Clinical outcomes in biopsy-proven nonalcoholic fatty liver disease patients: a multicenter registry-based cohort study. Clin Gastroenterol Hepatol. 2022;S1542\u20133565:22\u201300008. https:\/\/doi.org\/10.1016\/j.cgh.2002.01.002.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2786_CR12","doi-asserted-by":"publisher","first-page":"3861","DOI":"10.2147\/DMSO.S249949","volume":"13","author":"MA Hegazy","year":"2020","unstructured":"Hegazy MA, Mogawer SM, Alnaggar ARLR, Ghoniem OA, Abdel Samie RM. Serum LPS and CD163 biomarkers confirming the role of gut dysbiosis in overweight patients with NASH. Diabetes Metab Syndr Obes. 2020;13:3861\u201372.","journal-title":"Diabetes Metab Syndr Obes"},{"key":"2786_CR13","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1182\/blood.V99.1.378","volume":"99","author":"HJ M\u01ffller","year":"2002","unstructured":"M\u01ffller HJ, Peterslund NA, Graversen JH, Moestrup SK. Identification of the hemoglobin scavenger receptor\/CD163 as a natural soluble protein in plasma. Blood. 2002;99:378\u201380.","journal-title":"Blood"},{"key":"2786_CR14","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1189\/jlb.72.4.711","volume":"72","author":"KA Hintz","year":"2002","unstructured":"Hintz KA, Rassias AJ, Wardwell K, Moss ML, Morganelli PM, Pioli PA, et al. Endotoxin induces rapid metalloproteinase-mediated shedding followed by up-regulation of the monocyte hemoglobin scavenger receptor CD163. J Leukoc Biol. 2002;72:711\u20137.","journal-title":"J Leukoc Biol"},{"key":"2786_CR15","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1530\/EC-17-0296","volume":"7","author":"NR Rittig","year":"2018","unstructured":"Rittig NR, Svart M, Jessen N, M\u00f8ller N, M\u00f8ller HJ, Gr\u00f8nb\u00e6k H. Macrophage activation markers sCD163 correlates with accelerated lipolysis following LPS exposure: a human-randomised clinic trial. Endocr Connect. 2018;7:107\u201314.","journal-title":"Endocr Connect"},{"key":"2786_CR16","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1002\/hep.24127","volume":"53","author":"EM Brunt","year":"2011","unstructured":"Brunt EM, Kleiner DE, Wilson LA, Belt P, Neuschwander-Tetri BA, NASH Clinical Research Network (CRN). Nonalcoholic fatty liver disease (NAFLD) activity score and the histologic diagnosis in NAFLD: distinct clinicopathologic meanings. Hepatology. 2011;53:810\u201320.","journal-title":"Hepatology"},{"key":"2786_CR17","doi-asserted-by":"publisher","first-page":"1313","DOI":"10.1002\/hep.20701","volume":"41","author":"DE Kleiner","year":"2005","unstructured":"Kleiner DE, Brunt EM, Van Natta M, Behling C, Contos MJ, Cummings OW, et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology. 2005;41:1313\u201321.","journal-title":"Hepatology"},{"key":"2786_CR18","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1530\/EC-14-0107","volume":"4","author":"LP S\u01ffrensen","year":"2015","unstructured":"S\u01ffrensen LP, Parkner T, S\u01ffndergaard E, Bibby BM, M\u00f8ller HJ, Nielsen S. Visceral obesity is associated with increased soluble CD163 concentration in men with type 2 diabetes mellitus. Endocr Connect. 2015;4:27\u201336.","journal-title":"Endocr Connect"},{"key":"2786_CR19","doi-asserted-by":"crossref","unstructured":"Kazankov K, Berrera F, M\u01ffller HJ, Rosso C, Bugianesi E, David E et al. The macrophage activation marker sCD163 is associated with morphological disease stages in patients with non-alcoholic fatty liver disease. Liver Int. 2016;36:1449 \u2013 557.","DOI":"10.1111\/liv.13150"},{"key":"2786_CR20","doi-asserted-by":"publisher","first-page":"1012","DOI":"10.1016\/j.jhep.2019.06.031","volume":"71","author":"C Rosso","year":"2019","unstructured":"Rosso C, Kazankov K, Younes R, Esmaili S, Marietti M, Sacco M, et al. Crosstalk between adipose tissue insulin resistance and liver macrophages in non-alcoholic fatty liver disease. J Hepatol. 2019;71:1012\u201321.","journal-title":"J Hepatol"},{"key":"2786_CR21","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1080\/00365513.2017.1346823","volume":"77","author":"S R\u01ffdgaard-Hansen","year":"2017","unstructured":"R\u01ffdgaard-Hansen S, St George A, Kazankov K, Bauman A, George J, Gr\u00f8nb\u00e6k H, et al. Effects of lifestyle intervention on soluble CD163, a macrophage activation marker, in patients with non-alcoholic fatty liver disease. Scand J Clin Lab Invest. 2017;77:498\u2013504.","journal-title":"Scand J Clin Lab Invest"},{"key":"2786_CR22","doi-asserted-by":"publisher","first-page":"1293","DOI":"10.1111\/jgh.12943","volume":"30","author":"K Kazankov","year":"2015","unstructured":"Kazankov K, Tordjman J, M\u01ffller HJ, Vilstrup H, Poitou C, Bedossa P, et al. Macrophage activation marker soluble CD163 and non-alcoholic fatty liver disease in morbidly obese patients undergoing bariatric surgery. J Gastroenterol Hepatol. 2015;30:1293\u2013300.","journal-title":"J Gastroenterol Hepatol"},{"key":"2786_CR23","doi-asserted-by":"publisher","first-page":"e114","DOI":"10.1038\/ctg.2015.36","volume":"6","author":"JL Mueller","year":"2015","unstructured":"Mueller JL, Feeney ER, Zheng H, Misdraji J, Kruger AJ, Alatrakchi N, et al. Circulating soluble CD163 is associated with steatohepatitis and advanced fibrosis in nonalcoholic fatty liver disease. Clin Transl Gastroenterol. 2015;6:e114.","journal-title":"Clin Transl Gastroenterol"},{"key":"2786_CR24","first-page":"49","volume":"30","author":"R De Vito","year":"2012","unstructured":"De Vito R, Alisi A, Masotti A, Ceccarelli S, Panera N, Citti A, et al. Markers of activated inflammatory cells correlate with severity of liver damage in children with nonalcoholic fatty liver disease. Int J Mol Med. 2012;30:49\u201356.","journal-title":"Int J Mol Med"},{"key":"2786_CR25","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1111\/ijpo.252","volume":"10","author":"K Kazankov","year":"2015","unstructured":"Kazankov K, M\u01ffller HJ, Lange A, Birkebaek NH, Holland-Fischer P, Solvig J, et al. The macrophage activation marker sCD163 associated with changes in NAFLD and metabolic profile during lifestyle intervention in obese children. Pediatr Obes. 2015;10:226\u201333.","journal-title":"Pediatr Obes"},{"key":"2786_CR26","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1111\/j.1440-1746.2009.05854.x","volume":"24","author":"AG Testro","year":"2009","unstructured":"Testro AG, Visvanathan K. Toll-like receptors and their role in gastrointestinal disease. J Gastroenterol Hepatol. 2009;24:943\u201354.","journal-title":"J Gastroenterol Hepatol"},{"key":"2786_CR27","doi-asserted-by":"publisher","first-page":"2275","DOI":"10.1111\/jgh.15487","volume":"36","author":"M Iwaki","year":"2021","unstructured":"Iwaki M, Kessoku T, Ozaki A, Kasai Y, Kobayashi T, Nogami A, et al. Gut microbiota composition associated with hepatic fibrosis in non-obese patients with non-alcoholic fatty liver disease. Gastroenterol Hepatol. 2021;36:2275\u201384.","journal-title":"Gastroenterol Hepatol"},{"key":"2786_CR28","doi-asserted-by":"publisher","first-page":"e1221557","DOI":"10.1080\/2162402X.2016.1221557","volume":"5","author":"A Ambade","year":"2016","unstructured":"Ambade A, Satishchandran A, Saha B, Gyongyosi B, Lowe P, Kodys K, et al. Hepatocellular carcinoma is accelerated by NASH involving M2 macrophage polarization mediated by hif-1 \u03b1 induced IL-10. Oncoimmunlogy. 2016;5:e1221557.","journal-title":"Oncoimmunlogy"},{"key":"2786_CR29","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1016\/j.cell.2009.12.052","volume":"140","author":"EJ Park","year":"2010","unstructured":"Park EJ, Lee JH, Yu GY, He G, Ali SR, Holzer RG, et al. Dietary and genetic obesity promote liver inflammation and tumorigenesis by enhancing IL-6 and TNF expression. Cell. 2010;140:197\u2013208.","journal-title":"Cell"},{"key":"2786_CR30","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1038\/nrgastro.2013.183","volume":"10","author":"GA Michelotti","year":"2013","unstructured":"Michelotti GA, Machado MV, Diehl AM. NAFLD, NASH and liver cancer. Nat Rev Gastroenterol Hepatol. 2013;10:656\u201365.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"2786_CR31","doi-asserted-by":"publisher","first-page":"615599","DOI":"10.3389\/fmed.2020.615599","volume":"7","author":"RH Gantzel","year":"2021","unstructured":"Gantzel RH, Kj\u00e6r MB, Laursen TL, Kazankov K, George J, et al. Macrophage activation markers, Soluble CD163 and mannose receptor, in Liver Fibrosis. Front Med. 2021;7:615599.","journal-title":"Front Med"},{"key":"2786_CR32","first-page":"OC32","volume":"11","author":"M Watany","year":"2017","unstructured":"Watany M, Badawi R, Elkhalawany W, Abd-Elsalam S. Study of dickkopf-1 (DKK-1) gene expression in hepatocellular carcinoma patients. J Clin Diagn Res. 2017;11:OC32\u20134.","journal-title":"J Clin Diagn Res"},{"key":"2786_CR33","doi-asserted-by":"publisher","first-page":"4945","DOI":"10.1007\/s11033-020-05521-4","volume":"47","author":"M Elhendawy","year":"2020","unstructured":"Elhendawy M, Abdul-Baki EA, Abd-Elsalam S, Hagras MM, Zidan AA, et al. MicroRNA signature in hepatocellular carcinoma patients: identification of potential markers. Mol Biol Rep. 2020;47:4945\u201353.","journal-title":"Mol Biol Rep"},{"key":"2786_CR34","doi-asserted-by":"publisher","first-page":"896","DOI":"10.2174\/1568009619666190718141647","volume":"19","author":"F El-Gebaly","year":"2019","unstructured":"El-Gebaly F, Abou-Saif S, Elkadeem M, Helmy A, Abd-Elsalam S, et al. Study of serum soluble programmed death ligand 1 as a prognostic factor in Hepatocellular Carcinoma in Egyptian Patients. Curr Cancer Drug Targets. 2019;19:896\u2013905.","journal-title":"Curr Cancer Drug Targets"}],"container-title":["BMC Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12876-023-02786-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12876-023-02786-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12876-023-02786-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,10]],"date-time":"2023-05-10T13:09:24Z","timestamp":1683724164000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcgastroenterol.biomedcentral.com\/articles\/10.1186\/s12876-023-02786-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,10]]},"references-count":34,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["2786"],"URL":"https:\/\/doi.org\/10.1186\/s12876-023-02786-4","relation":{},"ISSN":["1471-230X"],"issn-type":[{"value":"1471-230X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,10]]},"assertion":[{"value":"27 July 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 April 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 May 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All experimental protocols were approved by the Research Ethics Committee of Kawasaki Medical School (No. 2088) and complied with the guidelines of the 1975 Helsinki Declaration. Each patient provided informed consent signed at the time of histological diagnosis of the liver and opted out on the Internet.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interest"}}],"article-number":"143"}}